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Abstract
Protein ubiquitylation has been demonstrated to play a
vital role not only in mediating protein turnover but also
in modulating protein activity. The stability and activity
of the tumor suppressor p53 and of the oncoprotein
c-Myc are no exception. Both are regulated through
independent ubiquitylation by several E3 ubiquitin
ligases. Interestingly, p53 and c-Myc are functionally
connected by some of these E3 enzymes and their
regulator ARF, although these proteins play opposite
roles in controlling cell growth and proliferation. The
balance of this complex ubiquitylation network and its
disruption during oncogenesis will be the topics of
this review.
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Introduction: The Need for Cellular Balance
Thousands of years ago, ancient Chinese and Greek physi-
cians saw disease as a result of imbalance in the body. This
imbalance was defined as a struggle between the ‘‘yin’’
(negative) and ‘‘yang’’ (positive) forces in traditional Chinese
medicine. Amazingly, this ancient theory on how illness
might occur can now be demonstrated at the molecular
level. In this regard, tumorigenesis is one of the best
examples. Now, it is generally believed that cancer evolves
from the gradual imbalance of tumor suppressors (yin) and
oncoproteins (yang) due to sequential genetic and/or epige-
netic alterations often initiated by physical, chemical, or
biologic carcinogens in a cell, or from inherited genetic
errors. It has been proposed that these alterations occur
sequentially in at least three or more genes, leading to the
development of human cancers (reviewed in Hahn and
Weinberg [1]). A number of such yin and yang protein reg-
ulators have been identified over the past 30 years. Two
intensively studied representatives are the tumor suppres-
sor p53 and the oncoprotein c-Myc. Because they play
opposing roles in controlling cell growth and proliferation,
the balanced regulation of these two proteins becomes
critical for the cell to grow without undergoing transforma-
tion. Over the last decade, biochemical, cellular, and genetic
studies have revealed strikingly complex regulation net-
works for both p53 and c-Myc within the cell. One such
regulation is ubiquitylation. This review will focus on the ubiq-
uitylation of these two proteins and will summarize the most
recent progress toward understanding how the cell may regu-
late p53 and c-Myc by employingmultiple ubiquitin ligases while
also discussing the relevance of their imbalance to oncogenesis
(see Table 1 for summary).
Regulation of the Tumor Suppressor p53 (Yin) by Multiple
Ubiquitin Ligases: the Tumor Suppressor p53
and Its Turnover
The tumor-suppressor protein p53 can be regarded as a yin
factor because of its inhibitory role in cell growth, proliferation,
and migration. This role is crucial in preventing neoplasia and
tumorigenesis. Inactivation of p53 by gene-targeting depletion
in mice or by an inherited heterozygous point mutation in
Li-Fraumeni syndrome leads to tumor formation in various
tissues [2–5]. In addition, somatic alterations of p53 that
lead to its inactivation are associated with more than 50%
of all types of human cancers, most of which are malignant
[6–8]. Conversely, activation of p53 in response to various
external (chemotherapeutics or carcinogens) and internal
stresses prevents tumor formation and progression [8–10].
The tumor-suppressive function of p53 is attributed to its multi-
potent capability of inducing apoptosis, cell cycle arrest, senes-
cence, and DNA repair, as well as its ability to suppress
angiogenesis and metastasis [8–10]. Most of these cellular
effects are mediated by effector proteins whose expression
at the RNA level is stimulated by p53 [8,11], although p53 can
also directly induce mitochondria-mediated apoptosis [12–14]
and probably participate in DNA repair directly [15]. Hence,
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p53 acts as the principal ‘‘guardian’’ of the genome to protect
an organism from oncogenesis [8].
However, an overabundance of yin is detrimental to overall
balance. This statement is very true for p53. Due to its nega-
tive effect on cell growth, overactive or excess p53 is detri-
mental to normal cells. Thus, the p53 protein needs to be
maintained at a low and inert level with a half-life off30 min-
utes in order for cells to grow under normal physiological
conditions. To keep this balance of p53 maintained, cells
have developed an elegant proteolytic mechanism.
Proteolysis is executed by a complicated ubiquitylation-
dependent 26S proteasome system with multiple proteins
[16]. In principal, protein ubiquitylation is catalyzed through a
cascade of enzymatic reactions. Ubiquitin (a 76–amino acid
polypeptide) is activated through the ATP-dependent for-
mation of a thiol ester bond with a cystine residue of the
ubiquitin-activating enzyme E1. Then, activated ubiquitin is
transferred to a cystine residue of the ubiquitin-conjugating
enzyme E2 and conjugated to a lysine residue(s) of a protein
substrate by the ubiquitin protein ligase E3. The polyubiqui-
tylated protein, with a minimum chain of four ubiquitins, has a
final destination at the 26S proteasome for degradation [17].
E3 plays a pivotal role in identifying a specific protein
substrate for ubiquitylation. At least four classes of E3 have
been reported to recognize p53 as a target for ubiqui-
tylation, including RING, U-box, HECT (homology to E6AP
C-terminal domain), and cullin/ROC1–containing ubiquitin
ligase complexes (Figure 1). Therefore, p53 is under tight
control by these E3 proteins, although it remains to be ver-
ified if some newly discovered E3s, as described below, are
authentic to p53 in vivo and if they act in a concerted fashion
to regulate p53 stability under certain physiological or
pathological conditions. Elucidating the mechanisms of this
control is vital for understanding how cells activate p53 to
prevent transformation.
Ubiquitylation of p53 by the Oncoprotein MDM2
The oncoprotein MDM2 is encoded by the mdm2 gene,
which was originally identified on a mouse double-minute
chromosome in the 3T3DM cell line [18]. It is the most in-
tensively studied E3 ubiquitin ligase that negates p53 func-
tion [19]. MDM2 possesses several key functional domains.
The N-terminal domain of MDM2 mediates its binding to
p53 [20,21]. The central acidic domain of MDM2 recently
has been shown to be essential for MDM2-mediated p53
degradation, but not ubiquitylation [22–25]. In the C-terminal
side of the acidic domain are a zinc finger domain with
unknown function and a RING domain with intrinsic E3 ligase
activity [26]. The MDM2 protein also contains a nuclear
localization signal (NLS) and a nuclear export signal that
are responsible for shuttling MDM2 between the cytoplasm
and the nucleus, and possibly for regulating p53 activity
[27,28]. Within the RING domain, a small region of amino
acids (464–471) contains a nucleolar localization signal
sequence [29]. Almost all of these functional domains are
critical for the MDM2 suppression of p53 function.
MDM2 can inhibit p53’s function through several of the
following mechanisms. MDM2 can specifically bind to the
N-terminal transcription activation domain of p53 [20,21] and
directly block its transcriptional activity [21,30,31]. In addition,
this binding initiates p53 ubiquitylation by MDM2, leading to
proteasome-mediated p53 degradation [26,32]. MDM2 can
also relocalize p53 to the cytoplasm where p53 is unable to
function as a transcriptional regulator [33–36]. Finally, it has
been shown that MDM2 associates with p53, and possibly
with histones, promoting monoubiquitylation of histone H2B
[37] on the promoters of target genes, therefore inhibiting
p53’s transcriptional activity [37,38]. Interestingly, the ex-
pression of MDM2 is activated by p53 [39,40]. Thus, MDM2
acts as a negative feedback regulator of p53 [41,42]. This
feedback regulation is validated by two gene-targeting
studies, which show that depleting the p53 gene rescues
the lethality of mdm2 knockout mice [43,44].
Although the general concept of the MDM2–p53 loop is
well accepted, it remains obscure how MDM2 precisely
degrades p53 in cells. Currently, it is debatable where
MDM2 mediates the degradation of p53 and whether
MDM2 works alone to mediate this degradation in cells. As
to the first question, several studies propose that MDM2
Figure 1. A diagram showing that multiple ubiquitin E3 ligases target p53 for
ubiquitylation. Bars indicate ubiquitylation and the functional suppression of
p53, whereas arrows indicate the transcriptional activation of the ubiquitin E3
ligase by p53.
Table 1. Summary of E3 Ubiquitin Ligases for p53 and c-Myc.




p53 (yin) MDM2 RING 1 + Oncogene
PirH2 RING 1 ? ?
COP1 RING 1 ? ?
CHIP U-box 1 ? ?
E6AP HECT 2 ? ?
ARF-BP1/HectH9 HECT 1 + ?
Cullin 7 Cul 2–4? ? ?
Cul5–Roc1–
E1B55K
Cul 4 ? ?
c-Myc
(yang)
Skp2 RING 4 + Oncogene
Fbw7 RING 4  Tumor
suppressor
ARF-BP1/HectH9 HECT 1 + Oncogene?
(+) Promotes cell growth; () suppresses cell growth; (?) unsure or untested.
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mediates p53 degradation in both the nucleus and the
cytoplasm [45–47]. However, a later study suggests that
MDM2 only monoubiquitylates p53, possibly at multiple
lysines on its C-terminus [48] in the nucleus, and then trans-
fers this form of p53 to the cytoplasm for polyubiquitylation
and degradation [35]. A new question derived from this model
is whether MDM2 acts by itself to mediate p53 polyubiquity-
lation in the cytoplasm. If not, two candidate proteins may fill
this gap. One is p300 [49,50]. p300 was shown to act as a
potential E4 enzyme and to mediate subsequent polyubiqui-
tylation and degradation by cooperating with MDM2 [49].
However, this protein has never been shown to exist in the
cytoplasm; therefore, it is a less likely contender, although it
remains possible that p300 may assist MDM2 in polyubiqui-
tylating p53 in the nucleus.
Another likely candidate is MDMX, a protein that typically
resides in the cytoplasm. MDMX is a homolog of MDM2 [51].
Albeit MDMX lacks demonstrable E3 ubiquitin ligase activity
[22], it works as a partner of MDM2, possibly to enhance
p53’s ubiquitylation and degradation [52]. The essential role
of MDMX in the MDM2–p53 loop is also established by
double knockout studies, showing that deleting the p53 gene
rescues the lethal phenotype ofmdmx knockoutmice [53,54].
Again, it remains uncertain whether MDMX accelerates
MDM2-dependent p53 polyubiquitylation in the cytoplasm.
This speculation is seemingly contradicted by the fact that
MDMX is imported to and degraded in the nucleus by MDM2
in response to ionizing irradiation [55,56]. Although there are
some important pieces that are still missing in the puzzle that
would provide a unified model of MDM2-mediated p53 ubiq-
uitylation, it is likely that MDM2may ubiquitylate p53 primarily
in the nucleus and perhaps in the cytoplasm as well, with
p53’s monoubiquitylation or polyubiquitylation depending on
the stoichiometry of these proteins and/or the existence of
other helpers, such as MDMX.
Amyriad of questions involving the ubiquitination of p53 by
MDM2 remain. Another area that requires more examination
is the precise enzymatic mechanism of this ubiquitylation.
Furthermore, direct evidence demonstrating that ubiquity-
lated p53 molecules are destined for proteasome-mediated
degradation in cells is missing [57]. Regardless of unsolved
problems, it is reasonable to say that the oncoprotein MDM2,
as a physiological antagonist of p53, is a positive regulator of
cell growth (Figure 1). However, MDM2 is not the only
negative regulator of p53, as several other associated E3
ubiquitin ligases have been identified recently.
Ubiquitylation of p53 by Other E3 Ligases
Ring domain ligases Using differential display and affinity
purification approaches, two more members of the RING
finger E3 ligase family, PirH2 [58] and COP1 (constitutive
photomorphogenic 1), have been identified, respectively, to
monitor p53 stability [59]. PirH2 and COP1 both associate
with and ubiquitylate p53 independently, also without re-
quiring the aid of MDM2. Notably different from MDM2, the
PirH2 central region binds to the central sequence-specific
DNA-binding domain of p53. Although deleting the RING
finger abolishes PirH2 E3 ligase activity toward p53, this
mutant is still able to repress p53’s transactivation activity
[58]. This observation suggests that PirH2 may interfere with
the interaction of p53 with its DNA elements by competing for
the DNA-binding domain of p53. However, an intact RING
finger domain is necessary for COP1 to suppress p53 activity
by ubiquitylating this protein, as the RING finger–truncated
COP1 was no longer able to ubiquitylate p53 and to sup-
press p53’s activity [59]. Like MDM2, pirh2 and cop1 genes
are also transcriptional targets of p53 (Figure 1). Thus, both
proteins appear to be feedback regulators of p53, although
the biologic meaning of these regulatory processes requires
further investigation. It will also be important to learn whether
PirH2 and COP1 are oncoproteins, as well as negative
regulators of p53, in vivo.
HECT domain ligases E6AP is the first known ubiquitin E3
ligase for p53 and was originally identified as a human
papilloma virus protein E6–associated protein in cervical
carcinoma (HeLa) cells [60]. Human papilloma viruses 16
and 18 are highly related to the pathogenesis of cervical
carcinoma (90%). These viruses encode two transforming
oncoproteins E6 and E7, which directly bind to the tumor
suppressors p53 and pRb, respectively, and suppress their
functions [61,62]. After papilloma virus infection, the E6
protein associates with and recruits the HECT domain protein
E6AP to p53 in host cells to accelerate its ubiquitylation and
degradation. Unlike MDM2, which only serves as a platform
for the E2 to transfer activated ubiquitin to p53, E6AP
possesses a special C-terminal domain that is capable of
catalyzing the transfer of ubiquitin from the E2 to a substrate
[63]. E6AP does not recognize p53 directly. In normal cells
without virus infection, E6AP does not ubiquitylate and de-
grade p53. Therefore, E6AP is a negative regulator of p53
only after cellular infection with papilloma virus.
Most recently, a new HECT member, ARF-BP1/HectH9,
has been reported to target p53 as well [64] and will be
discussed in Convergence of p53 and c-Myc by ARF and
the ARF-BP1/HectH9 E3 Ligase section.
U-box ligases Another E3 ligase, CHIP (carboxyl terminus
of Hsc70-interacting protein), has been reported to induce
p53 degradation [65]. CHIP ubiquitylates p53 in vitro in the
presence of Hsc70 andE2 (UbcH5b). Although bothwild-type
p53 and R175H mutant p53 are targeted by CHIP, CHIP
appears to be more efficient in decreasing the level of mutant
p53 than that of wild-type p53 because this p53 mutant is
unfolded and Hsc70 often chaperones unfolded peptides
[66–70]. Therefore, Hsc70 may serve as a bridge for this
mutant and CHIP, facilitating CHIP-mediated R175H–p53
ubiquitylation. As to wild-type p53, Hsc70 may use the same
mechanism to facilitate the CHIP ubiquitylation of unfolded
p53s, which are a small fraction of the highly expressed
protein. This study suggests that CHIP-mediated p53 ubiq-
uitylation may be coupled to protein synthesis, as nascent
peptides are often unfolded. Although this model is provoc-
ative, additional studies are necessary to demonstrate the
physiological meaning of p53 regulation by CHIP, particularly
its relationship with cancer.
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Cullin-containing ligases Two cullin-containing ubiquitin
ligase complexes have been reported to ubiquitylate p53.
This type of complex usually consists of four components,
including cullin, ROC (the RING E3 ligase), and two other
proteins, forming a functional complex [71]. Interestingly, two
adenoviral proteins, E4orf6 and E1B55K, cooperate in tar-
geting p53 for ubiquitylation and degradation [72]. Purifica-
tion of E4orf6-associated proteins has revealed a novel p53
ligase complex containing cullin 5, elongins B and C, E4orf6,
E1B55K, and ROC1. This complex is remarkably similar to
the von Hippel-Lindau tumor suppressor and SCF E3 com-
plexes [72,73]. Thus, in addition to the papilloma virus, the
adenovirus also encodes viral oncoproteins, such as EIB55K,
that suppress p53 activity [74] by degrading it through the
ubiquitin-dependent proteasome pathway. By doing so,
viruses would keep host cells alive for the sake of their own
replication and life cycle during infection.
Besides adenovirus, human cells also use a cullin-
containing complex to target p53. This complex contains
cullin 7 [75] and appears tomonoubiquitylate or diubiquitylate
p53 in vitro and in cells. However, this ubiquitylation sup-
presses p53 activity without affecting p53 stability. Although
it remains unclear exactly how this complex regulates the
activity of p53, it is possible that the monoubiquitylation or the
diubiquitylation of p53 by this complex may inhibit p53
transcriptional activity by interfering with the interaction of
p53 with DNA. Surprisingly, cullin 7 resides in the cytoplasm
but does not recruit p53 into this cellular compartment,
leaving the puzzle of where p53 ubiquitylation actually
occurs. This study, although interesting, addsmore questions
to the waiting list for future investigations.
Regulation of p53 Ubiquitin Ligases
As described above, half a dozen E3 ligases or ligase
complexes have been identified to ubiquitylate p53. Although
many of the mechanisms underlying these ubiquitylations
remain largely unaddressed, the overall outcome is the same:
suppression of p53 function. The cell could overcome this
suppression and activate p53 to mediate cell cycle arrest and
apoptosis inmanyways. The easiest waywould be to reverse
this ubiquitylation. Indeed, a deubiquitylase called HAUSP
(herpesvirus-associated ubiquitin-specific protease) has
been identified to deubiquitylate p53, leading to p53 sta-
bilization and activation [76]. However, because HAUSP also
deubiquitylates MDM2 and its partner MDMX, knocking
down this ubiquitin hydrolase stabilizes and activates p53
as well [77,78]. HAUSP seems to reverse MDM2-mediated
ubiquitylation specifically, as it has no effect on p53 ubiquity-
lation by E6AP [79]. Whether it has an effect on p53 ubiq-
uitylation by other RING finger E3 ligases, as mentioned
above, is still an open question. In addition to this reverse
reaction, other posttranslational modifications (such as phos-
phorylation, methylation, acetylation, sumoylation, or neddy-
lation), in response to various stresses and protein–protein
interactions, are also believed to play various roles in stabi-
lizing and activating p53 by blocking theMDM2–p53 loop (for
details, see later sections and Refs. [9,11,80,81]). Recently, it
has been shown that 14-3-3g can bind to MDMX, which is
phosphorylated at serine 367 by Chk1 in response to UV
irradiation, and this binding results in the suppression of
MDMX-enhanced p53 ubiquitylation by MDM2 [82]. In con-
trast, ionizing radiation activatesChk2, which phosphorylates
the same serine and initiates 14-3-3–MDMX binding, result-
ing in the MDM2-mediated degradation of MDMX in the
nucleus [83]. Even though the mechanisms in both cases
are unclear and await further investigation, their outcomes
are the same: p53 activation [82–84]. It would be interesting
and important to learn whether stress signals can also
activate p53 by inhibiting other E3 ligases. These multiple
levels of the ubiquitin-mediated regulation of p53 not only
reflect the complexity of this network but also provide a
remarkable molecular paradigm for the yin–yang balance in
the cell. A second system that serves as an apt example of
fine-tuned regulation and is an appropriate balance to the
discussion of p53 as amajor tumor suppressor is the pathway
regulating a major oncoprotein, c-Myc.
Regulation of the c-Myc Oncoprotein (Yang) by Multiple
Ubiquitin Ligases
The c-Myc Oncoprotein and Its Turnover
The c-Myc oncoprotein can be considered the yang factor
due to its positive role in promoting cell growth and prolifer-
ation and its subsequent opposition to p53. It is a basic helix–
loop–helix leucine zipper (bHLH/LZ) transcription factor that
is responsible for regulating a variety of genes whose protein
products are involved in cell growth, proliferation, differenti-
ation, apoptosis, and neoplastic transformation [85,86]. The
N-terminal transcriptional activation domain (TAD) of c-Myc
contains two conserved segments, Myc box (MB) I and II,
which are crucial for all biologic activities [87]. The C-terminal
bHLH/LZ domain of c-Myc mediates sequence-specific DNA
recognition of E-box elements (CACGTG) (Figure 2). How-
ever, c-Myc does not work alone and forms a heterodimer
with its partner protein Max [88–90]. The c-Myc/Max hetero-
dimer activates the transcription of many target genes. Max
also acts as a transcriptional repressor when forming a
heterodimer with one of the Mad family members that binds
to the same E box sequence elements. In such a way, the
Max–Mad complex antagonizes the function of the c-Myc–
Max complex [91].Max is ubiquitously expressed and present
in stoichiometric excess to c-Myc, whereas the level of Myc
and Mad is highly regulated during cell growth. Thus, the
Myc–Mad ratio determines whether Max heterodimerizes
with c-Myc to promote cell growth or with Mad to inhibit cell
growth [92]. More complex than these regulations, the
c-Myc–Max complex also counteracts the transactivation
activity of another zinc finger transcription factor called
Miz-1, repressing a specific set of Miz-1 target genes
[89,93]. This repressive activity of c-Myc also requires Max
[94–97]. Hence, c-Myc possesses transcriptional activation
and repression activities toward specific target genes.
These activities of c-Myc are highly linked to its positive
role in controlling cell cycle [86] and ribosomal biogenesis
[98–100]. Consistent with this notion, c-Myc levels are
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high during embryogenesis and in rapidly dividing cells, but
considerably low in quiescent and differentiating cells. Homo-
zygous deletion of the c-myc gene is lethal to mice at E9.5–
10.5 days [101]. In addition, c-Myc–deficient cells no longer
proliferate [102,103]. Conversely, overexpression of c-Myc
inhibits cell differentiation independent of its ability to promote
cell proliferation [104,105]. However, c-Myc also induces
apoptosis when cells are under stress or when cultured with
limited survival signals [106,107]. Hence, c-Myc is essential
for cell growth and embryogenesis, although it also plays a
role in apoptosis under stress conditions.
In contrast to the tumor-suppressing function of p53,
c-Myc promotes uncontrolled cell growth and subsequent
tumorigenesis. Abnormal overexpression of c-Myc due to
chromosomal translocations, gene amplification, or viral in-
sertion at the c-myc locus is highly associated with several
types of human cancers [108–110]. Constitutive over-
expression of c-Myc in cells inhibits differentiation and in-
duces neoplastic transformation [111,112]. Moreover, c-myc
transgenic mice develop lymphoid malignancies [113]. In
addition, induced overexpression of c-myc either in the epi-
dermis [114], in hematopoietic lineages [115], or in pancre-
atic islet b cells [116] of inducible c-myc transgenic mice
leads to neoplastic, premalignant, and malignant pheno-
types. In contrast, when c-myc expression is turned off in
these mice, these tumorigenic phenotypes spontaneously
remit [114–116]. These studies demonstrate that deregula-
tion of c-Myc level or activity favors cell transformation and
tumorigenesis. Therefore, tight regulation of the c-Myc level
is essential for preventing cells from undergoing hyper-
plasia and consequent neoplasia. To do so, the cells have
evolvedmultiple mechanisms, including transcriptional, post-
transcriptional (mRNA stability and translation), and post-
translational (protein stability) regulations [110], to regulate
the level and activity of c-Myc. Only ubiquitin-mediated
regulation of c-Myc will be discussed here because this topic
is the concern of this review, and because this particular
c-Myc modification is highly relevant to c-Myc’s response to
growth stimuli and tumorigenesis.
As mentioned above, ubiquitylation is an exceedingly
powerful tool for the cell to master both a potent tumor
suppressor and an influential oncogene to achieve homeo-
stasis. Like p53 [117,118], c-Myc is also an extremely short-
lived protein with a half-life of less than 30 minutes in
cells [119]. Its fast turnover is carried out by the ubiquitin-
dependent proteasome system as well [120–122]. As for
other transcriptional factors whose TADs also serve as
degradation signals (degrons) [123] (reviewed in Muratani
and Tansey [124]), the N-terminal TAD of c-Myc, harboring
two conserved MBI and MBII domains, is also involved in the
regulation of c-Myc stability [121,125,126]. Although it is still
debatable how these two motifs work together, or inde-
pendently, to modulate c-Myc turnover [121,125,126,127],
the consensus seems to be that they are crucial for c-Myc
ubiquitylation and degradation. Over the past 3 years,
three ubiquitin ligases, SCFSkp2 [128,139,130], SCFFbw7
[131–134], and ARF-BP1/HectH9 [135], have been iden-
tified to contact the TAD domain, leading to c-Myc ubiquity-
lation (Figure 2). As detailed below, SCFFbw7 ubiquitylates
and degrades c-Myc in a phosphorylation-dependentmanner
[132,133], whereas SCFSkp2, as well as ARF-BP1/HectH9,
ubiquitylates c-Myc and regulates its transcriptional activity
[128,130,135]. Therefore, both p53 and c-Myc are regulated
through several ubiquitylation-dependent pathways, reflect-
ing the importance of protein stability to cellular harmony.
Ubiquitylation of c-Myc by SCFFbw7 Regulates Its Stability
In contrast to p53’s case, where phosphorylation is gen-
erally believed to prevent its degradation [136–139], phos-
phorylation has been shown to positively and negatively
regulate the stability of c-Myc [140–144]. These regulatory
steps are performed through a sequential phosphorylation at
serine (S) 62 and threonine (T) 58 in the MBI motif of c-Myc in
response to growth signals [143]. Interestingly, c-Myc levels
display a bell-shaped induction curve in response to serum
stimulation [145]. This induction is regulated byRas through a
dual mechanism. First, the serum-activated Ras triggers the
immediate early response of the Raf–MEK–ERK kinase
cascade, which in turn leads to the S62 phosphorylation of
c-Myc [143] and to c-Myc’s consequent stabilization. In
addition, Ras can activate the PI3K/AKT kinase cascade that
leads to c-Myc stabilization by blocking the GSK3b kinase–
activated c-Myc degradation pathway.
This degradation process involves multiple steps. It starts
with the phosphorylation of c-Myc at T58 by GSK3b
[140–144]. This phosphorylation facilitates the recruitment
of a prolyl isomerase, Pin1, to c-Myc. Pin1 then catalyzes
cis– trans isomerization at proline (P) 63 of c-Myc, and
subsequent conformational change allows the PP2A phos-
phatase to dephosphorylate c-Myc at S62 [146]. Finally,
phosphorylated T58 and dephosphorylated S62 serve as
a dock to recruit a T58 phosphorylation–dependent E3
ubiquitin ligase complex, called SCFFbw7 [131–134], to
Figure 2. A schematic diagram showing the functional domains of the c-Myc
protein and its regulation by multiple ubiquitin E3 ligases. c-Myc contains an
N-terminal TAD, as well as C-terminal basic (B), helix – loop–helix (HLH), and
leucine zipper (LZ) domains. The central domain contains a PEST region.
There are two conserved MBI and MBII motifs located in the TAD. Two
phosphorylation residues, T58 and S62, are shown. Fbw7 binds to MBI and
ubiquitylates c-Myc in a T58 phosphorylation–dependent manner. Skp2
targets c-Myc for ubiquitylation through both the MBII and C-terminal
domains. ARF-BP1/HectH9 ubiquitylates one or more of six lysine (K)
residues around the NLS region by binding to TAD. Ubiquitylation by SCFFbw7
results in the degradation of c-Myc, whereas ubiquitylation by SCFSkp2 and
HectH9/ARF-BP1 leads to the activation of c-Myc.
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ubiquitylate c-Myc (Figure 3). The importance of T58 in
regulating c-Myc stability is highlighted by the fact that T58
is frequently mutated in a subset of Burkitt’s lymphomas
[147–149]. Moreover, artificial mutation at T58 prevents c-
Myc ubiquitylation and degradation, as well as enhances
the oncogenic activity of c-Myc in vitro [125,126,144,150].
Strikingly, mice harboring the c-Myc T58A mutant develop
lymphomas at a significantly higher penetrance and re-
duced latency than mice with the wild-type c-myc transgene
[151]. Thus, growth factors in sera can activate Ras, which
turns on two kinase cascades. One of them mediates S62
phosphorylation and the other blocks T58 phosphorylation.
In doing so, Ras can protect c-Myc from being degraded by
the SCFFbw7 complex, consequently leading to c-Myc stabili-
zation (Figure 3).
Therefore, the SCFFbw7 complex is a critical player in the
business of c-Myc turnover. This complex contains an F-box
protein, termed Fbw7, that is a human ortholog of yeast
Cdc4 [131–134]. Although how this complex exactly de-
grades c-Myc remains to be studied, it has been shown that
Fbw7 directly interacts with the c-Myc MBI domain in a T58
phosphorylation–dependent manner. Overexpression of
Fbw7 destabilizes wild-type, but not T58-mutated, c-Myc.
Conversely, knocking down Fbw7 leads to the accumulation
of c-Myc levels and enhances c-Myc transactivational ac-
tivity. Similarly, the Drosophila archipelago (ago) protein, a
fly ortholog of human Fbw7, interacts with dMyc. Mutations
in ago result in elevated dMyc protein levels and massive
growth of tissues with increased cell size and number [131].
These studies indicate that the regulation of c-Myc by the
SCFFbw7 complex is evolutionarily conserved.
c-Myc is a nuclear protein, but recent evidence suggests
that it may be degraded in the nucleolus, a subnuclear
compartment where rRNA biogenesis takes place. A Fbw7
isoform, Fbw7g, was found to colocalize with c-Myc in the
nucleolus [134]. Specific knockdown of the Fbw7g isoform by
siRNA increases the nucleolar level of c-Myc and the size of
targeted cells. It is possible that c-Myc may shuttle between
the nucleoplasm and the nucleolus, and that ubiquitylation,
the proteasome-mediated degradation of c-Myc, or both may
occur in the nucleolus. Consistent with its inhibitory role in
regulating c-Myc turnover, Fbw7 has been shown to be a
potential tumor suppressor [152] (see the text below for
more discussion). Thus, Fbw7 acts as regulatory factor for
maintaining the balance of c-Myc.
Ubiquitylation of c-Myc by SCFSkp2 Regulates
Its Transactivational Activity
Unlike p53, the ubiquitylation of c-Myc does not always
mean its physical destruction or functional repression. In-
stead, this modification by another SCF complex, SCFSkp2,
increases the activity of c-Myc [128–130]. This effect is
executed through the interaction of the Skp2 subunit of the
SCFSkp2 complex with the MBII and bHLH-LZ domains of
c-Myc [128,130]. In contrast to the association of the SCFFbw7
complex with the MBI domain of c-Myc (see above), this
interaction is phosphorylation-independent [128–130]. Al-
though SCFSkp2 has been shown to mediate c-Myc degrada-
tion, this complex can also function as a coactivator of c-Myc
by ubiquitylating it and enhancing its transcriptional activity.
This dual, yet seemingly contradictory, role of SCFSkp2 in
regulating c-Myc stability and activity has been postulated to
be important for coupling the proteasome system with tran-
scription. Consistent with this idea are the data showing that
c-Myc also interacts with a proteasome subunit called Sug1,
and this interaction positively affects c-Myc activity [129].
Furthermore, chromatin immunoprecipitation analyses re-
veal that c-Myc may recruit Skp2, ubiquitylated proteins,
and AAA ATPase (APIS) components from the 19S regula-
tory subunit of the proteasome to the endogenous cyclin D2
promoter, which is a c-Myc target [128]. Therefore, the MBII
domain of c-Myc is not only involved in controlling its stability
but also important for regulating its activity. Indeed, several
coactivators, such as TRRAP-associated hGCN5 or TIP60-
containing histone acetyltransferase complexes, have been
Figure 3. A diagram showing growth signal –mediated c-Myc phosphoryla-
tion and ubiquitylation pathways. Growth signals such as serum stimulation
activate RAS. The RAS/Raf/MEK/ERK kinase cascade phosphorylates c-Myc
at S62. The RAS-PI3K/Akt cascade inhibits GSK3 activity. GSK3 mediates
the phosphorylation of c-Myc at T58. Phosphorylation of T58 recruits the Pin1
prolyl isomerase, which may catalyze cis – trans isomerization at the P63
bond. This conformational change facilitates the targeting of c-Myc by PP2A
phosphatase, which dephosphorylates c-Myc at S62. Phosphorylation of T58
and dephosphorylation of S62 serve as signals that trigger subsequent
ubiquitylation and degradation of c-Myc by the SCFFbw7 complex.
Ubiquitylation of p53 and c-Myc Dai et al. 635
Neoplasia . Vol. 8, No. 8, 2006
shown to bind to MBII and to mediate the histone H4 acet-
ylation of c-Myc target genes, leading to their expression
[153–156]. Moreover, the TIP48/TIP49 ATPases in chroma-
tin remodeling complexes also interact with the MBII domain
of c-Myc [157]. However, it remains unknown how these
coactivators interplay with SCFSkp2 in regulating c-Myc ac-
tivity and how c-Myc acetylation affects its ubiquitylation
during transcription under normal physiological conditions.
These are important issues for future exploration.
It is intriguing that Skp2 mediates both the proteasomal
degradation and the transactivational activity of c-Myc. How
Skp2 is able to perform both functions is still a mystery.
Although no definite answers are available thus far, a few
more pieces of evidence further indirectly support this
transcription-coupled proteasomal degradation mechanism.
Surprisingly, inhibition of c-Myc turnover by the proteasome
inhibitor MG132 leads to suppression of c-Myc’s transactiva-
tional activity, even though c-Myc levels increase [100]. In
addition, the 19S base ATPases and the lid Rpn7 subunit, as
well as the 20S (a2 subunit) particles, are recruited to the
cyclin D2 promoter by c-Myc [128,129]. These studies sug-
gest that the 26S proteasomemay degrade c-Myc at its target
promoters once this transcriptional factor fulfills its duty to
activate transcription of its target genes. Alternatively, once
recruiting the proteasome to its promoters, c-Myc may need
to be destroyed to allow the proteasome-mediated transcrip-
tional activation of its target genes. SCFSkp2 participates in
both degradation and transcription. This type of regulation
has also been shown for other transcriptional factors, such
as GCN4, Vp16, and Gal1-10, in yeast [158–161]. Hence,
ubiquitylation of c-Myc by the SCFSkp2 complex mediates not
only its degradation but also its transcriptional activity.
Although this model is very attractive and interesting, it
also raises a number of new questions, in addition to the
questionsmentioned above. For instance, is this regulation of
c-Myc by SCFSkp2 responsive to growth signals? Do SCFSkp2
and SCFFbw7 interplay with each other in regulating c-Myc
stability and activity? Do they target the same lysine residues
in c-Myc for ubiquitylation? In addition, is it possible that
c-Myc stability may be regulated through a postubiquitylation
or a ubiquitylation-independent mechanism [126]? A more
radical question is whether p53 activity or stability is also
regulated through the transcription-coupled proteasome
pathway. It would not be surprising if this speculation will
turn out to be true, as MDM2 has been shown to associate
with p53 at the target promoter [37,38]. Addressing these
questions would certainly advance our understanding of the
molecular details underlying c-Myc or p53 regulation by these
E3 ubiquitin ligases.
Convergence of p53 and c-Myc by ARF and the
ARF-BP1/HectH9 E3 Ligase
Although p53 and c-Myc play opposite roles in cell growth
control and are regulated by independent E3 ubiquitin
ligases, as described above, these two proteins are func-
tionally linked through a tumor suppressor called ARF (alter-
native reading frame of p16INK, also called p14arf in humans
and p19arf in mice). ARF is a nucleolar protein andmay play a
role in rRNA processing by inhibiting B23 function [162,163].
It has been shown that c-Myc induces the expression of ARF
at the level of mRNA and that ARF, in turn, activates p53
[164–167]. In addition, it has been shown that ARF induces
p53 by blocking the MDM2–MDMx–p53 feedback loop
[168–170]. ARF’s activation of p53 contributes to its role in
suppressing tumorigenesis. The tumor-suppressive role of
ARF is further verified by at least two forms of genetic
evidence. First, germline mutations in p14arf occur in 20%
to 40% of human familial melanomas [171,172]. Second,
arf-null mice are highly prone to cancer development
[173,174]. These studies have two implications: 1) that ARF
functions as a sensor of oncogenic stress, such as deregu-
lated c-Myc activation or expression, to activate p53 against
c-Myc–mediated cell transformation, and 2) that c-Myc may
induce apoptosis in an ARF–p53–dependent fashion in
response to nutrient deprivation. This c-Myc–ARF–p53
pathway presents a graceful molecular model of the yin–
yang relationship. However, the relationship between p53
and c-Myc is far more complex than this relatively simplified
version. Another E3 ligase is also involved.
Recently, three studies unveiled a member of the HECT
E3 ligase family, named ARF-BP1 (ARF-binding protein 1;
also called HectH9) and Mule (Mcl1 ubiquitin ligase E3)
[64,135,175], which ubiquitylates three distinct protein sub-
strates (a combined term ARF-BP1/HectH9 will be used here
for the sake of simplicity). This E3 ligase is a nuclear protein
with a molecular mass of 482 kDa, whose gene was originally
identified and partially cloned as Lasu1/Ureb1 [176]. Two of
three substrates were identified as p53 and c-Myc [64,135].
Interestingly, ARF-BP1/HectH9 directly binds to and ubiquity-
lates p53, as well as c-Myc, in vitro and in cells [64,135]. ARF-
BP1/HectH9 was also demonstrated as an E3 ligase for both
p53 and c-Myc, as ablation of this E3 protein by siRNA pre-
vents ubiquitylation of p53 and c-Myc in cells. However, the
outcomes of their respective ubiquitylations are completely
divergent. Ubiquitylation of p53 by ARF-BP1/HectH9, likely
through lysine 48 of ubiquitin, commits p53 to proteasome-
mediated degradation [64], whereas ubiquitylation of c-Myc
by ARF-BP1/HectH9, through lysine 63 of ubiquitin, enhances
the transcriptional activity of c-Myc without degrading it [135].
Thus, ARFBP1/HectH9 serves as a novel linker between p53
and c-Myc. The overall outcome of this diverse regulation of
these yin and yang factors by ARFBP1/HectH9 is to promote
cell growth and proliferation [64,135].
Again, ARF also joins this new tangle because ARF was
used as a bait to fish out ARF-BP1 and because it inhibited
p53 ubiquitylation by this E3 ligase [64]. Although ARF
suppresses MDM2-mediated p53 ubiquitylation, as men-
tioned above, both p53 ubiquitylation by ARF-BP1/HectH9
and suppression of this ubiquitylation by ARF have nothing to
do with MDM2. Therefore, ARF can activate p53 by sup-
pressing either MDM2-mediated or ARF-BP1/HectH9–
mediated p53 ubiquitylation [64,170]. Because depleting
ARF-BP1/HectH9 induces p53 at a much greater level than
does knocking down MDM2 or Pirh2 in cells [64], it has been
proposed that ARF-BP1 may play a more important role in
636 Ubiquitylation of p53 and c-Myc Dai et al.
Neoplasia . Vol. 8, No. 8, 2006
monitoring the physiological level of p53without any apparent
stress [177]. This speculation is stimulating and requires
further examination, particularly in animals. However, it may
be considerably challenging to test this model in vivo, as
ARFBP1/HectH9 also targets two other substrates, c-Myc
and Mcl-1, and probably more unidentified ones.
It remains untested whether ARF also suppresses c-Myc
activity by interfering with ARF-BP1/HectH9–mediated
c-Myc ubiquitylation. However, it would not be astonishing if
it does so, as ARFhas been shown to directly suppress c-Myc
activity [178,179]. Regardless of this remaining issue,
another c-Myc suppressor, Miz-1, does inhibit ARF-BP1/
HectH9–mediated c-Myc ubiquitylation, possibly by compet-
ing with the binding of c-Myc for this E3 ligase. Miz-1 is not
the substrate for ARF-BP1/HectH9 [135]. Interestingly,
ARF-BP1/HectH9–mediated c-Myc ubiquitylation is required
for the transcriptional coactivator p300 to bind to c-Myc at
c-Myc target promoters, as the c-MycK6R mutant, which is
not ubiquitylated by this E3 ligase, is unable to recruit p300 to
the same promoters. In this aspect, it appears that ARF-BP1/
HectH9 may facilitate c-Myc–dependent transcription by
ubiquitylating this transcriptional factor. Taken together, these
studies [64,135] demonstrate that ARF-BP1/HectH9 serves
as another node of convergence of p53 and c-Myc and
another example of how the yin–yang forces of the cell
are balanced through ubiquitylation regulation. The fulcrum
supporting this balance is the tight regulation of ARF. Disrup-
tion of this network could lead to uncontrolled cell growth
and consequent tumorigenesis (see Implications of p53
and c-Myc Ubiquitin Ligases in Tumorigenesis section for
further discussion).
Nucleolar Proteins Regulate Ubiquitylation of Both
p53 and c-Myc
In addition to ARF [166,168,170,178,179], there are other
nucleolar proteins that have also been shown to regulate
p53 and c-Myc. These proteins appear to sense a type of
stress called ribosomal stress. Ribosomal stress is often
caused by external and internal signals or chemicals that
interfere with rRNA synthesis, rRNA processing, and ribo-
some assembly. This type of stress has been shown to
activate p53 aswell [180–183]. For example, overexpression
of dominant-negative mutants of Bop1, a nucleolar protein
critical for rRNA processing and ribosome assembly [180],
inhibits 28S and 5.8S rRNA formation and causes a defect in
ribosome assembly in NIH3T3 fibroblast cells. Consistent
with this result, deleting the gene encoding the S6 protein,
a component of the 40S ribosomal subunit, may disrupt
ribosomal assembly in T lymphocytes [184,185], causing
ribosomal stress. Consequently, these cells undergo p53-
dependent G1 cell cycle arrest [181,182,184]. In addition, a
low dose of actinomycin D, which specifically inhibits RNA
polymerase I, can stall rRNA synthesis and ribosome as-
sembly. By doing so, this anticancer drug stimulates p53
activity without triggering N-terminal phosphorylation of p53
[183,186]. Furthermore, ARF directly inhibits rRNA process-
ing, which may also generate ribosomal stress, thus contrib-
uting to p53 activation, in addition to its role in regulating the
MDM2–p53 and ARF-BP1/HectH9–p53 pathways, as dis-
cussed above. These studies support the ribosomal stress–
p53 activation pathway. However, the molecular mechanism
underlying this pathway has been unknown until recent
studies, including ours, revealed several nucleolar proteins
that may participate in this pathway.
These nucleolar proteins include the ribosomal proteins
L11, L23, and L5 [187–191]. Normally, these L proteins are
assembled with rRNA and other ribosomal proteins into the
60S large subunit of the ribosome in the nucleolus and are
then exported to the rough endoplasmic reticulum for protein
translation, together with the 40S small subunit. In response
to ribosomal stress, such as serum starvation or inhibition
of RNA polymerase I activity by actinomycin D, L11, L23,
and L5 are released from the nucleolus to associate di-
rectly with MDM2, mostly in the nucleoplasm [187–189,192].
By doing so, these ribosomal proteins can inhibit MDM2-
mediated p53 ubiquitylation, increasing p53 level and activity
in human cells. As a result, the cells undergo p53-dependent
G1 arrest [187–192]. Despite these discoveries, little is
known about the mechanism underlying the regulation of
MDM2 E3 ubiquitin ligase activity by these L proteins. Some
clues suggest that the L proteins may interfere with MDM2’s
ubiquitin ligase activity by interacting with the central acidic
domain of this protein [187–189,191] because it has been
shown that this acidic domain contributes toMDM2-mediated
p53 degradation [22–25]. Surprisingly, not all of these L
proteins appear to use the same mechanism; our recent
studies suggest that only L23 and L5 appear to suppress
MDM2 autoubiquitylation in cells [245]. L11 seems to use a
postubiquitylation mechanism [245] similar to that used by
ARF [193]. Regardless of these remaining issues, it is con-
ceivable that the L proteins also play a role in the ribosomal
stress–p53 signaling pathway, besides their essential func-
tion during protein translation.
In addition, another nucleolar protein, called B23 or nucle-
ophosmin, which is ubiquitously expressed in all cells and
has been implicated in rRNA processing, ribosomal protein
assembly, and transport [194,195], also activates p53
[196,197]. Similar to the L proteins, B23 interacts directly
with MDM2 and inhibits MDM2-mediated p53 ubiquitylation
and degradation in response to UV [196], resulting in p53-
dependent cell growth arrest. Furthermore, it was found that
the normal nucleolar structure was disrupted in cells treated
with 11 of 13 different agents that induced p53 stabiliza-
tion [198]. Because all of these reagents can cause nu-
clear accumulation of B23 through unknown mechanisms
[198,199], it has been proposed that mammalian cells may
have evolved a sensing mechanism that can be activated
when the nucleolus is disrupted (nucleolus stress) [198]. The
tumor suppressor p53 is a downstream responder of this
sensing system, as loss of this p53 response can result in
unrestrained cellular proliferation [200,201]. This nucleolus
stress–p53 pathway remains to be elucidated in parallel to
the DNA-damaging p53 activation mechanism and is impor-
tant for protecting cells from undergoing uncontrolled cell
growth. It is possible that different nucleolar stress reagents
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may activate p53 through different nucleolar proteins. Recent
proteomic analyses of the nucleolus have identified a number
of novel nucleolar proteins that might be rRNA processing
and ribosome assembly factors [202,203]. Thus, we specu-
late that more nucleolar proteins will be probably uncovered
to regulate the MDM2–p53 pathway in the near future.
Furthermore, in the interest of maintaining balance, the nu-
cleolus is also a common territory of c-Myc.
The nucleolus is a workshop for ribosomal biogenesis,
which is a highly controlled process requiring coordinated
transcription by all three RNA polymerases (Pol) to ensure
efficient and accurate production of ribosomes [204,205].
Several studies have acclaimed that c-Myc is a new and
critical player in this process. In addition to regulating RNA
Pol II–catalyzed transcription [206–209], c-Myc also en-
hances polymerase I–catalyzed rRNA synthesis [98–100]
and polymerase III–mediated 5S and tRNA transcription
in the nucleolus [210]. Strikingly, these nucleolar activities
of c-Myc are all regulated by ARF. ARF binds to c-Myc and
inhibits c-Myc transactivation activity [178,179]. Thus, ARF
is thought of as a feedback regulator of c-Myc in response
to oncogenic stress (Figure 4). Not only c-Myc activity but
also c-Myc stability is most likely monitored in the nu-
cleolus. As mentioned in Regulation of the c-Myc Onco-
protein (Yang) by Multiple Ubiquitin Ligases section, the
nucleolar Fbw7g may mediate c-Myc ubiquitylation and deg-
radation in the nucleolus [134].
In summary, both p53 and c-Myc are associated with
ribosomal biogenesis. Under unstressed conditions, c-Myc
activity is required for driving normal ribosomal biogenesis in
order for cells to grow and to proliferate. In response to
ribosomal stress, nucleolar proteins, such as ARF, L11,
L23, L5, or B23, are released from the nucleolus to crosstalk
with MDM2 and to repress its activity. As a result, p53 is
stabilized and activated to prevent cell growth and prolifera-
tion. Therefore, the coupling of ARF to proteasomal degra-
dation and the stability of two major regulators of cellular
homeostasis maintain the delicate balance of the cell.
Implications of p53 and c-Myc Ubiquitin Ligases
in Tumorigenesis
Unbalanced regulation of p53 (yin) and c-Myc (yang) forces
cells toward the path of oncogenesis. This notion is sub-
stantially supported not only by the fact that inactivation of
p53, as well as activation of c-Myc, has been consistently
demonstrated to lead to carcinogenesis [8,10,86,109] but
also by the increasing volume of evidence showing that their
aforementioned regulators are highly relevant to cancer
formation. As discussed above, inactivation of ARF by dele-
tion mutation and knockout also leads to tumor growth in
certain tissues. Although it remains to be clarified if the
ribosomal proteins L11, L5, and L23 may function as tumor
suppressors, mutations of some ribosomal proteins have
been linked to tumorigenesis in zebrafish [211]. The rele-
vance of several E3 ubiquitin ligases in the p53 and c-Myc
pathways to cancer is discussed below.
MDM2 is an Oncoprotein
The oncogenic activity of MDM2 is reflected through its
capability to immortalize and to transform rat embryonic
fibroblasts, in cooperation with Ras [212]. In addition, over-
expression of MDM2 converts NIH 3T3 cells into tumor cells
that can develop into xenografted tumors in mice [213].
Consistently, amplification and overexpression of MDM2
have been found in a variety of human tumors, particularly
in soft tissue sarcomas, carcinomas, leukemias, lymphomas,
and breast and lung cancers [214–219]. The tumorigenic
potential of MDM2 is primarily attributed to its ability to inhibit
the tumor-suppressor function of p53, as discussed above.
Fbw7 Is a Haploinsufficient Tumor Suppressor
Because SCFFbw7 targets multiple oncoproteins, such as
c-Myc [131–134], cyclin E [220–222], c-Jun [223,224], and
Notch [225,226], for ubiquitylation and degradation, it acts
as a tumor suppressor (reviewed in Minella and Clurman
[152]). Indeed, Fbw7 is mutated in 8 of 51 (15.7%) cases of
human endometrial carcinomas [227] and in 22 of 190
(11.6%) cases of colorectal cancers [228], as well as in
several ovarian [221] and breast cancer [222] cell lines.
Interestingly, the majority of mutations occur either at the
F-box (Skp1-binding domain) or at WD40 repeats (substrate
recognition domain) of Fbw7, highlighting the importance of
these domains in tumorigenesis. In addition, the chromo-
some locus 4q32 containing the Fbw7 gene is deleted in over
31% of human cancers [229]. Because homozygous deletion
of this gene results in embryonic lethality, Fbw7 is a haploin-
sufficient tumor suppressor. This conclusion is further sup-
ported by a recent study showing that radiation-induced
lymphomas from p53+/, but not p53/, mice display fre-
quent loss of heterozygosity and a 10% mutation rate in the
Fbw7 gene. Furthermore, Fbw7 heterozygote mice are more
susceptible to radiation-induced tumorigenesis, in compari-
son with either p53+/ or p53/ mice [230]. Despite the fact
that mutations of Fbw7 often coexist with elevated levels of
total and phosphorylated cyclin E and that overexpression
of cyclin E results in genomic instability [231] that correlates
with cancer presentation and poor prognosis in murine and
human [232–235] systems, it remains to be investigated
whether c-Myc activation may have a direct contribution to
the formation of human cancers due to loss of one copy of the
Fbw7 gene.
Figure 4. Regulation of p53 and c-Myc transcription factors by nucleolar
proteins. Bars indicate inhibition; arrows denote the functional activation of
c-Myc.
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Skp2 is an Oncoprotein
The oncogenic activity of Skp2 is highly associated with its
role in controlling the turnover of another tumor suppressor
p27kip1 [236,237], which inhibits Cdk2/cyclin E activity during
the G1-phase to S-phase transition. Deletion of the p27
Kip1
gene almost completely rescued the overreplicative pheno-
type of skp2 knockout mice [238], suggesting that p27Kip1 is a
major target of Skp2. In addition, overexpression of Skp2
induces malignant phenotypes in transgenic mice [239,240].
Although it is still unaddressedwhether c-Myc is also involved
in the oncogenesis induced by Skp2, it is quite possible that
c-Myc may play a part in Skp2-induced tumorigenesis.
The Possibility of ARF-BP1/HectH9 as an Oncoprotein
In light of its role in suppressing p53 activity and in
enhancing c-Myc activity, it can be predicted that ARF-BP1/
HectH9 may act as an oncoprotein. In line with this hypoth-
esis is the fact that this protein is overexpressed in 80% (16
of 20) of breast cancer cell lines [64], as well as in a large
number of primary human tumors, including breast (43%),
lung (46%), colon (52%), liver (18%), pancreatic (20%), and
thyroid (9%) carcinomas [135]. The level of ARF-BP1/HectH9
is closely correlated with tumor progression, as its over-
expression is detected in 33% (9 of 27) of adenomas and
49% (42 of 85) of adenocarcinomas, but not in the normal
epithelium and in polyps [135]. However, more studies are
critical to fully establish its role as an oncoprotein and to
determine whether ARF-BP1/HectH9 can be used as a
marker for cancer progression or whether its gene is am-
plified in human cancers.
Conclusion: The Balance Maintained
Themolecular anatomy of the p53 and c-Myc pathways using
biochemical, cell biologic, and genetic tools over the past
decades has unraveled an overwhelmingly complex network
that functionally bridges the two distinct transcription factors
with opposing roles in controlling cell growth. In this network,
ARF and ARF-BP1/HectH9 appear to play a key role as
the fulcrum providing a sustained balance between the
cell growth promoted by c-Myc and the cell growth suppres-
sion executed by p53. On one hand, ARF-BP1/HectH9 is ac-
tivated to turn on c-Myc activity, but can also turn off p53
through ubiquitylation, although it is still unclear how this E3
ubiquitin ligase is activated (Figure 4). However, when c-Myc
is aberrantly overactive, such as in response toRas activation
(Fig. 3), it induces ARF, which in turn represses c-Myc activity
through crosstalk. Other than reducing c-Myc activity, ARF
also could inactivate the c-Myc helper, ARF-BP1/HectH9.
Additionally, ARF activates p53 by suppressing the E3 ligase
activities of both Mdm2 and ARF-BP1/HectH9. As a result,
the cell growth program is turned off. By doing so, ARF and
p53 act as the yin force to prevent cells from undergoing
uncontrolled growth and to suppress neoplasia provided by
the yang of c-Myc. However, repeated perturbation of yin and
yang through mechanisms such as inactivation of p53 and
ARF, or activation of c-Myc, MDM2, or ARF-BP/HectH9,
would gradually lead to cell transformation and oncogenesis.
For instance, two N-terminal mutation alleles of c-Myc iden-
tified in human Burkitt’s lymphoma fail to bind to the BH3-only
protein Bim and to effectively inhibit Bcl2 and thus lose their
ability to induce apoptosis but still promote cell proliferation
[151]. Because of this failure, these c-Myc mutant alleles are
able to evade the tumor suppression activity of p53, more
efficiently promoting lymphomagenesis, regardless of their
capability of inducing p53 level [151]. Thus, the interdepen-
dence and fluctuating balance between yin and yang are
represented in cellular homeostasis by p53–c-Myc networks
for the control of cell growth.
One ultimate benefit of identifying these positive and
negative growth regulators and of elucidating their interplay
in cell growth control is to divulge a broad spectrum of
molecular targets that are potentially useful for cancer diag-
nosis and antitumor drug development. For example, the
MDM2–p53 feedback loop has been used as a drug target
[241–244]. ARF-BP1/HectH9, as well as others (as de-
scribed in this review), may be a potential candidate for future
pharmacological studies, once its individual role in tumori-
genesis and its connections with specific tumors have been
firmly established. Yet because most of these proteins reside
in the nucleus or the nucleolus, it would be particularly
challenging to deliver effective drugs against them. Never-
theless, continued dissection of how individual molecules act
in maintaining the balance in cell growth control pathways for
the larger purpose of cellular harmony and homeostasis will
definitely lead to better and promising treatments for cancer in
the future.
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